2015
Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer
Abstract: SummaryBackground Modufolin® ([6R]-5,10-methylene tetrahydrofolate; [6R]-MTHF) is an endogenous biomodulator that is being developed as an alternative to leucovorin, a folate prodrug used in the treatment of colorectal cancer. The objective of this phase 1 dose de-escalation trial was to estimate the minimum tolerated dose of [6R]-MTHF to be used in combination with pemetrexed 500 mg/m2 in the neoadjuvant treatment of patients with rectal cancer. Methods Adult patients (≥18 years) with resectable rectal adenoc…
Search citation statements
Paper Sections
Select...
1
1
0
0
Citation Types
0
1
0
0
Year Published
Range
2018
2023
Publication Types
Select...
2
Relationship
0
2
Authors
Journals
Cited by 2 publications
(1 citation statement)
References 46 publications
0
1
0
0
Smart CitationsHow the paper below cites the one you are viewing
“…There are also different analogs for MTT in various stages of preclinical and clinical development [ 7 , 8 ]. Pemetrexed, a potent polyglutamate classic antifolate TS inhibitor formerly called LY23154 [ 9 ], is an interesting new antifolate.…”
Section: Introduction
mentioning
confidence: 99%
Abstract